论文部分内容阅读
卵巢恶性肿瘤是女性生殖系统三大恶性肿瘤之一,其发病率在女性生殖系统肿瘤中占第三位,而死亡率却高居首位。目前对于晚期卵巢癌(Ⅲ或Ⅳ期)多倾向于用新辅助化疗+肿瘤细胞减灭术+术后周期性化疗的治疗方法。但是,尽管多数患者在最初对化疗药物较敏感,但仍有60%~80%最终死于卵巢癌,这些患者大部分都对化疗药物产生了耐药性,在更换新的化疗方案初期是有效的,但最终仍会耐药。近年来,有关细胞凋亡抑制蛋白(cIAP,cellular inhibitors of apoptosis proteins)在卵巢癌复发耐药中的作用机制的研究越来越受到重视。研究证实,cIAP在耐药肿瘤细胞中呈高表达,并与多种因子共同参与形成了上皮性卵巢癌的耐药机制,抑制了化疗药物引起的肿瘤细胞的凋亡。这些发现为攻克卵巢癌的耐药机制提供了重要线索,也为卵巢癌化疗药物的应用指出了新的方向。
Ovarian malignant tumor is one of the three major malignant tumors of the female reproductive system, its incidence in the female reproductive system tumors accounted for third place, while the mortality rate is highest in the first place. Currently for advanced ovarian cancer (stage Ⅲ or Ⅳ) tend to use neoadjuvant chemotherapy + cytoreductive surgery + postoperative chemotherapy. However, while most patients initially become chemotherapy-sensitive, 60-80% of them eventually die of ovarian cancer, and most of these patients are resistant to chemotherapeutic agents and are effective early in the course of a new chemotherapy regimen But eventually it will be resistant. In recent years, more and more attention has been paid to the mechanism of action of cIAP (cellular inhibitors of apoptosis proteins) in the recurrence of ovarian cancer. Studies have confirmed that cIAP is highly expressed in drug-resistant tumor cells, and a variety of factors involved in the formation of epithelial ovarian cancer resistance mechanism, inhibition of chemotherapy-induced tumor cell apoptosis. These findings provide important clues for the mechanism of resistance to ovarian cancer and point out a new direction for the application of chemotherapy drugs for ovarian cancer.